NSABP B-49
Complete
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Principal Investigator
Patrick J. Flynn
Status
Complete
Date Opened To Accrual
April 4, 2012
Date Closed To Accrual
November 21, 2013
Disease Site
Breast [BR] Breast
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine if the TC regimen is non-inferior to the anthracycline-based chemotherapy regimens in terms of invasive disease-free survival (IDFS) by combining B-49 data with the TAC and TC arms of NSABP B-46-I/USOR 07132 and the data from USOR 06-090.
Patient Population
Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Target Accrual
1843
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
